Katrine Mørk Paulsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katrine Mørk Paulsen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Arnulf Soleng
Department of Virology, Norwegian Institute of Public Health, Oslo, Norway
2 shared publications - Daniel Růžek
Veterinary Research Institute Brno Czech Republic
2 shared publications - Jiří Salát
Veterinary Research Institute Brno Czech Republic
2 shared publications - Karen Angeliki Krogfelt
Department of Science and Environment, Roskilde University, Roskilde, Denmark
2 shared publications - Rose Vikse
Department of Virology, Norwegian Institute of Public Health, Oslo, Norway
2 shared publications - Åshild Kristine Andreassen
Department of Natural Science and Environmental Health, University of South-Eastern Norway, Bø, Norway; Department of Virology, Norwegian Institute of Public Health, Oslo, Norway
2 shared publications
Latest Publications
- Open Access
- 6 February 2026
- Published by Elsevier in Ticks and Tick-borne Diseases
- Vol. 17 (2) , 102609
Experimental evidence for milk-borne transmission of tick-borne encephalitis virus to suckling lambs
- 6 February 2026
- Published by Elsevier in Ticks and Tick-borne Diseases
- Vol. 17 (2) , 102609
Open AccessExperimental evidence for milk-borne transmission of tick-borne encephalitis virus to suckling lambs
- Open Access
A Retrospective Sero-Surveillance Study for Antibodies Against Tick-Borne Encephalitis Virus in Norway
Tick-borne encephalitis virus (TBEV) is an emerging pathogen that initially causes flu-like symptoms and can progress to central nervous system (CNS) infections. Tick-borne encephalitis (TBE) is an endemic disease in southern coastal counties with regular human cases, while the causative agent, TBEV, is prevalent in ticks in most of the coastal regions of Norway. This study was aimed to understand TBEV infection status across Norway including both TBE endemic and non-endemic areas. For this, we analyzed a total of 1940 residual serum samples from 19 counties of Norway (as of 2016). The samples were initially screened by ELISA, followed by virus neutralization tests for TBEV confirmation. We found a similar TBEV seroprevalence of 1.7% in TBE endemic and 1.6% in non-endemic areas. Since TBE cases are only reported from endemic regions, our findings suggest a potential subclinical or asymptomatic infection and underdiagnosis in non-endemic areas. Notably, only 43% of the ELISA-positive samples were confirmed by virus neutralization tests indicating that not all ELISA positives are true TBEV infections. Additionally, 137 samples of patients presenting with symptoms of CNS infections from a non-endemic area were included. Of these samples, 11 ELISA-positive samples were analyzed for cross-reactivity among flaviviruses. Cross-reactivity was detected with Dengue virus, West Nile Virus, and non-specific reactions. This underscores the importance of using multiple diagnostic tests to confirm TBEV infections. None of the patients with CNS infection was found to be TBE positive, and in the whole cohort, we found a low TBEV seroprevalence of 0.7%.
Open AccessA Retrospective Sero-Surveillance Study for Antibodies Against Tick-Borne Encephalitis Virus in Norway
Tick-borne encephalitis virus (TBEV) is an emerging pathogen that initially causes flu-like symptoms and can progress to central nervous system (CNS) infections. Tick-borne encephalitis (TBE) is an endemic disease in southern coastal counties with regular human cases, while the causative agent, TBEV, is prevalent in ticks in most of the coastal regions of Norway. This study was aimed to understand TBEV infection status across Norway including both TBE endemic and non-endemic areas. For this, we analyzed a total of 1940 residual serum samples from 19 counties of Norway (as of 2016). The samples were initially screened by ELISA, followed by virus neutralization tests for TBEV confirmation. We found a similar TBEV seroprevalence of 1.7% in TBE endemic and 1.6% in non-endemic areas. Since TBE cases are only reported from endemic regions, our findings suggest a potential subclinical or asymptomatic infection and underdiagnosis in non-endemic areas. Notably, only 43% of the ELISA-positive samples were confirmed by virus neutralization tests indicating that not all ELISA positives are true TBEV infections. Additionally, 137 samples of patients presenting with symptoms of CNS infections from a non-endemic area were included. Of these samples, 11 ELISA-positive samples were analyzed for cross-reactivity among flaviviruses. Cross-reactivity was detected with Dengue virus, West Nile Virus, and non-specific reactions. This underscores the importance of using multiple diagnostic tests to confirm TBEV infections. None of the patients with CNS infection was found to be TBE positive, and in the whole cohort, we found a low TBEV seroprevalence of 0.7%.